manual-prevencion

MANUAL SEOM DE PREVENCIÓN Y DIAGNÓSTICO PRECOZ DEL CÁNCER 151 10. BIBLIOGRAFÍA 1. Tubbs A, Nussenzweig A. Endogenous DNA Damage as a Source of Genomic Instability in Cancer. Cell. 2017 Feb 9;168(4):644-656. 2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646-74. 3. Slavin TP, Niell-Swiller M, Solomon I, Nehoray B, Rybak C, Blazer KR, Weitzel JN. Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management. Front Oncol. 2015 Sep 29;5:208. 4. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 May;17(5):405-24. 5. Fletcher O, Houlston RS. Architecture of inherited susceptibility to common cancer. Nat Rev Cancer. 2010 May;10(5):353-61. 6. Giardiello FM, AllenJI, Axilbund JE, Boland CR, Burke CA, Burt RW, et al. Guidelines on Genetic Evaluation andManagement of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2014;147:502–526. 7. Guía de Práctica Clínica en Cáncer Hereditario de la Comunitat Valenciana. Tercera edición (en imprenta). Servicio de Promoción de la Salud y Prevención en el Entorno Sanitario. Conselleria de Sanitat Universal i Salut Pública. Generalitat, 2017. 8. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality for Lynch syndrome in relatives. Genet Med 2009;11:35–41. 9. Genetic/Familial High-Risk Assessment: Colorectal. NCCN Guidelines Versión 2.2016. www.nccn.org/professionals/physician_gls/ genetics_colon.pdf. 10. Guillén-Ponce C, Serrano R, Sánchez-Heras AB, Teulé A, Chirivella I, Martín T, et al. Clinical guideline SEOM: hereditary colorectal cancer. ClinTransl Oncol. 2015; 17:962-71. 11. Jasperson KW, Patel SG, Ahnen DJ. APC-Associated Polyposis Conditions. GeneReviews ® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017. December 18, 1998; last updated February 2, 2017. 12.NielsenM, LynchH, InfanteE, BrandR.MUTYH-associatedpolyposisGeneReviews ® [Internet]. Seattle (WA):UniversityofWashington, Seattle; 1993-2017. October 4, 2012; Last Update: September 24, 2015. 13. Eng C. PTEN Hamartoma Tumor Syndrome. GeneReviews ® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017. November 29, 2001; Last Update: June 2, 2016. 14. Genetic/Familial High-Risk Assessment: Breast and Ovarian. NCCN Guidelines Versión 2.2017. www.nccn.org/professionals/ physician_gls/pdg/genetics_screening.pdf 15. McGarrityTJ, Amos CI, BakerMJ. Peutz-Jeghers Syndrome. GeneReviews ® [Internet]. Seattle (WA): University ofWashington, Seattle; 1993-2017. February 23, 2001; Last Update: July 14, 2016. 16. Llort G, Chirivella I, Morales R, Serrano R, Sanchez AB, Teulé A, et al. SEOMclinical guidelines in hereditary breast and ovarian cancer. ClinTransl Oncol. 2015; 17:956-61. 17. Paluch-Shimon S, Cardoso F, Sessa C, Balmaña J, Cardoso MJ, Gilbert F, Senkus E, on behalf of the ESMO Guidelines Committee. Prevention and screening in BRCAmutation carriers and other breast/ovarian hereditary cancer syndromes: ESMOClinical Practice Guidelines for cancer prevention and screening. Ann Oncol 27:v103-v110, 2016 18. Frantzen C, Klasson TD, Links TP, Giles RH. Von Hippel-Lindau Syndrome. GeneReviews ® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017. May 17, 2000; Last Update: August 6, 2015. 19. Marquard J, Eng C. Multiple Endocrine Neoplasia Type 2. GeneReviews ® [Internet]. Seattle (WA): University ofWashington, Seattle; 1993-2017. September 27, 1999; Last Update: June 25, 2015. 20. Giusti F, Marini F, Brandi ML. Multiple Endocrine NeoplasiaType 1. GeneReviews ® [Internet]. Seattle (WA): University ofWashington, Seattle; 1993-2017. 2005 Aug 31 [updated 2015 Feb 12]. 21. Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR et al. Endocrine Society. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97:2990-3011. Escalas de Niveles de evidencia y grados de recomendación que aparecen: GRADE Centre for Evidence-Based Medicine de Oxford (OCEBM) NCCN Infectious Diseases Society of America clinical practice guidelines (IDSA)